Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05C HYPNOTICS AND SEDATIVES
N05CJ Orexin receptor antagonists
N05CJ03 Daridorexant
D11887 Daridorexant hydrochloride (JAN/USAN) <JP>
USP drug classification [BR:br08302]
Sleep Disorder Agents
Sleep Promoting Agents
Orexin Receptor Antagonists
Daridorexant
D11887 Daridorexant hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D11887 Daridorexant hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03225 Orexin receptor antagonist
DG03119 Daridorexant
D11887 Daridorexant hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03119 Daridorexant
D11887 Daridorexant hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Orexin
HCRTR
D11887 Daridorexant hydrochloride (JAN/USAN) <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11887
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11887
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11887
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11887
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11887
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03225 Orexin receptor antagonist
DG03119 Daridorexant
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03119 Daridorexant